Fig. 1

Melanoma-specific antibody kinetics and overall survival in cohort 1. Antibody levels and kinetics in the sera of responders (R), non-responders (NR): Anti-NY-ESO-1 (a, b), anti-MelanA/MART1 (d, e), anti-TRP1/TYRP1 (g, h), anti-TRP2/TYRP2 (j, k), anti-gp100 (m, n). a, d, g, j, m: Antibody levels before treatment start. Differences between responders and non-responders were tested with Wilcoxon rank-sum tests. Bars represent means and 95% CI, and circles show data from individual patients. b, e, h, k, n: Differences between the three visits (i.e. change during checkpoint inhibitor therapy) were tested with Friedman tests for each patient group. Changes (Δ) in IgG levels from treatment start to the visit after 6–9 weeks were compared between responders and non-responders with Wilcoxon ranks sum tests; p-values for this test are given above those for every group. Bars represent means and 95% CI. c, f, i, l, o: Kaplan-Meier curves showing overall survival (OS) of patients with high vs. low antibody levels at therapy start. Grouping criteria (cutpoints) are given in graphs. Hazard ratios (HR) for high vs. low antibody levels are provided with p-values from log-rank tests